Article
Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Feb 2026
Mayer E L, Bidard F-C, Park Y H, Janni W, Ma C, Cristofanilli M, Iwata H, Bianchini G, Kalinsky K, Chia S, Brufsky A, Fasching P A, Nowecki Z, Chen S-C, Pascual J, Moreau L, Ruiz-Borrego M, Shai A, Karadurmus N, Sohn J H, Zhu Y, Leddin I, Miralles M S, Bartlett C H, Turner N
Abstract excerpt
BACKGROUND: In SERENA-6, switching from aromatase inhibitor (AI) to camizestrant with continuation of CDK4/6 inhibitor (CDK4/6i) guided by emergence of ESR1 mutations (ESR1-mut) during first-line AI-CDK4/6i in patients with hormone receptor (HR)-positive advanced breast cancer (ABC) resulted in statistically significant and clinically meaningful improvement in progression-free survival compared with AI-CDK4/6i...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.